注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Regeneron Pharmaceuticals Inc是一家综合性生物技术公司,致力于发现、发明、开发、制造和商业化治疗严重疾病的药物。其商业化药物和正在开发的候选产品旨在帮助患有眼病、过敏和炎症性疾病、癌症、心血管和代谢疾病、疼痛、血液病、传染病和罕见病的患者。其上市产品包括EYLEA(aflibercept)注射液、Dupixent(dupilumab)注射液、Libtayo(cemiplimab)注射液、Praluent(alirocumab)注射液、REGEN-COV、Kevzara(sarilumab)皮下注射液、Evkeeza(evinacumab)注射液、Inmazeb(atoltivimab) 、maftivimab和odesivimab-ebgn) 注射剂,用于皮下注射的ARCALYST(利洛那西普)注射剂和用于静脉输注的ZALTRAP(ziv-aflibercept)注射剂。该公司还提供Expresse服务保证和CloudCheck WiFi体验管理解决方案。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Joseph L. Goldstein | 83 | 1991 | Independent Director |
George D. Yancopoulos | 63 | 1998 | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
Leonard S. Schleifer | 70 | 1988 | Co-Founder, President, CEO & Co-Chairman |
George L. Sing | 74 | 1988 | Independent Director |
Michael S. Brown | 82 | 1991 | Independent Director |
Arthur Frederick Ryan | 80 | 2003 | Independent Director |
Huda Y. Zoghbi | 68 | 2016 | Independent Director |
Christine Ann Poon | 71 | 2010 | Lead Independent Director |
Bonnie L. Bassler | 61 | 2016 | Independent Director |
N. Anthony Coles | 63 | 2017 | Independent Director |
Craig B. Thompson | 70 | 2022 | Independent Director |
David P. Schenkein | 66 | 2023 | Director |
Kathryn W. Guarini | - | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核